JPRN-UMIN000002855已完成未知
A Phase II Study of Adjuvant Cisplatin and Gemsitabine in patients with completely resected stage II-IIIA Non-Small Cell Lung Cancer - A Phase II Study of Adjuvant Cisplatin and Gemsitabine in patients with completely resected stage II-IIIA Non-Small Cell Lung Cancer
Toracic Medical Oncology of Toracic Center Cancer Instiute Hospital Japanese Foundation Cancer Reseach0 个研究点目标入组 55 人开始时间: 2009年12月7日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 55
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •A recognized ILD or pulmonary fibrosis on X-rays.
研究者
相似试验
进行中（未招募）
不适用
Phase II study of neoadjuvant cisplatin and gemcitabine plus sorafenib for patients with transitional cell carcinoma of the bladder. - Sorafenib-CG in TCC of the bladderMedDRA version: 9.1Level: LLTClassification code 10005084Muscle-invasive transitional cell carcinoma of the bladder at clinical stage T>/=2N0.EUCTR2010-022653-41-ITISTITUTO NAZIONALE PER LA CURA TUMORI
进行中（未招募）
不适用
A trial of upfront chemotherapy followed by surgical resection in patients witk biliary tract cancerResectable Biliary Tract CarcinomaMedDRA version: 18.0Level: LLTClassification code 10017621Term: Gallbladder carcinoma localizedSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0Level: PTClassification code 10008593Term: CholangiocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0Level: LLTClassification code 10034446Term: Periampullary carcinoma resectableSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-002382-30-GBThe Clatterbridge Cancer Centre NHS Foundation Trust
进行中（未招募）
不适用
Phase II Trial of Neoadjuvent Cisplatin, Gemcitabine and Sunitinib Malate followed by radical cystectomy for transitional Cell Carcinoma (TCC) of the bladderoperable bladder cancer (T2 to T4a) lymph node negative diseaseEUCTR2008-006214-26-GBHoosier Oncology Group46
进行中（未招募）
2 期
Phase II Study of Cisplatin, Gemcitabine, and Necitumumab in Patients with Unresectable, Advanced or Recurrent Squamous Cell Carcinoma of the Lung after Combination of Immunotherapy and Chemotherapy.Squamous cell carcinomaon-small-cell lung cancerJPRN-jRCTs051200138Yoshioka Hiroshige45
已完成
不适用
Clinical phase II study of cisplatin plus gemcitabine followed by switch maintenance docetaxel for advanced squamous-cell lung cancerJPRN-UMIN000004297Okayama Lung Cancer Study Group40